LMAT has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
LMAT has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Net Income is the net profit that a company earns after deducting all costs and losses including cost of goods, SGA, DDA, interest expenses, non-recurring items and tax. LeMaitre Vascular's Net Income for the three months ended in Dec. 2023 was $8.5 Mil. Its Net Income for the trailing twelve months (TTM) ended in Dec. 2023 was $30.1 Mil.
Net Income is linked to the most popular Earnings per Share (Diluted) number. LeMaitre Vascular's Earnings per Share (Diluted) for the three months ended in Dec. 2023 was $0.38.
The historical data trend for LeMaitre Vascular's Net Income can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LeMaitre Vascular Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
Net Income | Get a 7-Day Free Trial | 17.93 | 21.22 | 26.91 | 20.64 | 30.11 |
LeMaitre Vascular Quarterly Data | ||||||||||||||||||||
Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | |
Net Income | Get a 7-Day Free Trial | 5.63 | 6.04 | 8.10 | 7.50 | 8.47 |
Net Income is the net profit that a company earns after deducting all costs and losses including cost of goods, SGA, DDA, interest expenses, non-recurring items and tax.
Net Income
= Revenue
- Cost of Goods Sold
- Selling, General, & Admin. Expense
- Research & Development
- Depreciation, Depletion and Amortization
- Interest Expense
- Non Operating Income (NRI) - Tax Expense + Others
= EBITDA
- Depreciation, Depletion and Amortization
- Interest Expense
- Non Operating Income (NRI) - Tax Expense + Others
= Operating Income
- Interest Expense
- Non Operating Income (NRI) - Tax Expense + Others
= Pre-Tax Income - Tax Expense + Others
LeMaitre Vascular's Net Income for the fiscal year that ended in Dec. 2023 is calculated as
Net Income | (A: Dec. 2023 ) | ||||||
= | Pre-Tax Income | + | Tax Provision | + | Net Income (Discontinued Operations) | + | Others |
= | 39.475 | + | -9.37 | + | 0 | + | -3.5527136788005E-15 |
= | 30.1 |
LeMaitre Vascular's Net Income for the quarter that ended in Dec. 2023 is calculated as
Net Income | (Q: Dec. 2023 ) | ||||||
= | Pre-Tax Income | + | Tax Provision | + | Net Income (Discontinued Operations) | + | Others |
= | 11.313 | + | -2.848 | + | 0 | + | 0 |
= | 8.5 |
Net Income for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $30.1 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LeMaitre Vascular (NAS:LMAT) Net Income Explanation
Net Income is the most widely cited number in reporting a company's profitability. It is linked to the most popular earnings-per-share (EPS) number through:
LeMaitre Vascular's Earnings per Share (Diluted) (EPS) for the quarter that ended in Dec. 2023 is calculated as
Earnings per Share (Diluted) (Q: Dec. 2023 ) | = | (Net Income | - | Preferred Dividends) | / | Shares Outstanding (Diluted Average) |
= | (8.465 | - | 0) | / | 22.459 | |
= | 0.38 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
EPS is most useful for companies that have:
A predictable businessThe dividend paid to preferred stocks needs to be subtracted from the total net income in the calculation of EPS because common stock holders are not entitled to that part of the net income.
Be Aware
Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred Net Income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.
Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.
If net earnings is less than 10%, likely to be in a highly competitive business.
Thank you for viewing the detailed overview of LeMaitre Vascular's Net Income provided by GuruFocus.com. Please click on the following links to see related term pages.
George W Lemaitre | director, 10 percent owner, officer: Chairman, President and CEO | 342 BUNKER HILL STREET, #2B, CHARLESTOWN MA 02129 |
Bridget A Ross | director | C/O HENRY SCHEIN, INC., 135 DURYEA ROAD, MELVILLE NY 11747 |
John A Roush | director | C/O GSI GROUP INC., 125 MIDDLESEX TURNPIKE, BEDFORD MA 01730-1409 |
Lawrence J Jasinski | director | SOTEIRA INC., 14 TECH CIRCLE, NATICK MA 01760 |
David B Roberts | director, officer: CFO and Director | 55 BRADFORD STREET, NEEDHAM MA 02492 |
Trent G Kamke | officer: Senior V. P., Operations | 61 WILLOWDEAN AVENUE, WEST ROXBURY MA 02132 |
Martha Shadan | director | 9201 W BROADWAY AVE, #650, MINNEAPOLIS MN 55445 |
Pellegrino Joseph P Jr | officer: Executive V.P. Finance | 68 BEACON STREET, BOSTON MA 02108 |
Michael H Thomas | director | P.O. BOX 2207, NOKOMIS FL 34274-2207 |
Peter R Gebauer | officer: President, International OP | AM WALDFELD 17, BAD SODEN 2M 65812 |
Michael T Wijas | officer: VP of Sales, The Americas | C/O LEMAITRE VASCULAR, INC., 63 SECOND AVENUE, BURLINGTON MA 01803 |
Lemaitre Cornelia W | director, officer: V.P., Human Resources,Director | 8 SUNSET ROCK ROAD, ANDOVER MA 01810 |
Russell D Hays | director | C/O BIOSOURCE INTERNATIONAL INC, 542 FLYNN RD, CAMARILLO CA 93012 |
Robert V Linden | officer: VP, North American Sales | 236 WOODEN BRIDGE ROAD, HOLLAND PA 18966 |
Thorndike William N Jr | director | HOUSATONIC PARTNERS, 800 BOYLSTON STREET, SUITE 2220, BOSTON MA 02199 |
From GuruFocus
By GuruFocus Research • 12-12-2023
By GuruFocus Research • 12-13-2023
By Robert Abbott • 07-20-2022
By GuruFocus Research GuruFocus Editor • 05-19-2023
By GlobeNewswire • 07-31-2023
By GlobeNewswire GlobeNewswire • 07-18-2022
By Marketwired • 09-21-2023
By sperokesalga sperokesalga • 06-06-2023
By Marketwired • 10-17-2023
By PurpleRose PurpleRose • 07-15-2022
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.